78 related articles for article (PubMed ID: 8416441)
1. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.
Leather AT; Studd JW; Watson NR; Holland EF
Obstet Gynecol; 1993 Jan; 81(1):104-7. PubMed ID: 8416441
[TBL] [Abstract][Full Text] [Related]
2. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
3. Add-back therapy in the treatment of endometriosis: the European experience.
Edmonds DK
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
[TBL] [Abstract][Full Text] [Related]
4. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
5. The need for add-back with gonadotrophin-releasing hormone agonist therapy.
Studd J; Leather AT
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():1-4. PubMed ID: 8916978
[TBL] [Abstract][Full Text] [Related]
6. The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study.
Leather AT; Studd JW; Watson NR; Holland EF
Gynecol Endocrinol; 1999 Feb; 13(1):48-55. PubMed ID: 10368798
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
[TBL] [Abstract][Full Text] [Related]
9. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
[TBL] [Abstract][Full Text] [Related]
10. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin.
Sillem M; Parviz M; Woitge HW; Kiesel L; Ulrich U; von Holst T; Runnebaum B; Ziegler R; Seibel MJ
Exp Clin Endocrinol Diabetes; 1999; 107(6):379-85. PubMed ID: 10543415
[TBL] [Abstract][Full Text] [Related]
11. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
12. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
14. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
[TBL] [Abstract][Full Text] [Related]
15. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
16. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
[TBL] [Abstract][Full Text] [Related]
17. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
18. Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial.
Franke HR; Snaaijer FF; Houben PW; van der Mooren MJ
Gynecol Endocrinol; 2006 Dec; 22(12):692-7. PubMed ID: 17162712
[TBL] [Abstract][Full Text] [Related]
19. Should add-back therapy for endometriosis be deferred for optimal results?
Kiesel L; Schweppe KW; Sillem M; Siebzehnrübl E
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():15-7. PubMed ID: 8916982
[TBL] [Abstract][Full Text] [Related]
20. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.
Rock JA; Truglia JA; Caplan RJ
Obstet Gynecol; 1993 Aug; 82(2):198-205. PubMed ID: 8336864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
